Medivir Q2 2023: Positive Signals from Fully Recruited Phase II - Redeye

In August, the Lenvima arm of the phase II study of fostrox in advanced liver cancer was fully recruited. Positive signals are emerging from readouts of the first ten patients. The first readout from all 15 patients will be published within a few months, which will be a major catalyst for the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/934944/medivir-q2-2023-positive-signals-from-fully-recruited-phase-ii?utm_source=finwire&utm_medium=RSS